BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 31063184)

  • 41. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    Masuda K; Ono A; Aikata H; Kawaoka T; Nelson Hayes C; Teraoka Y; Daijo K; Nakamura-Inagaki Y; Morio K; Fujino H; Kan H; Uchida T; Masaki K; Kobayashi T; Nakahara T; Makokha GN; Zhang Y; Nagaoki Y; Miki D; Tsuge M; Hiramatsu A; Imamura M; Abe-Chayama H; Kawakami Y; Ochi H; Chayama K
    J Gastroenterol; 2018 Jan; 53(1):107-118. PubMed ID: 28474222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma.
    Shao YY; Huang CC; Liang PC; Lin ZZ
    Asia Pac J Clin Oncol; 2010 Jun; 6(2):80-8. PubMed ID: 20565419
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Peng P; Wen B; Chen R; Deng X
    Turk J Gastroenterol; 2023 Apr; 34(4):311-321. PubMed ID: 37089046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report].
    Tsukamoto T; Kanazawa A; Shimizu S; Murata A; Sakae M; Kurihara S; Tashima T; Deguchi S; Nakai T; Kawasaki Y; Kioka K
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1878-80. PubMed ID: 26805203
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy.
    Yamashita T
    Clin Drug Investig; 2012 Aug; 32 Suppl 2():15-23. PubMed ID: 22873624
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials.
    Huang Y; Zhang L; He M; Lai Z; Bu X; Wen D; Li Q; Xu L; Wei W; Zhang Y; Zhou Z; Chen M; Guo R; Shi M; Kan A
    Technol Cancer Res Treat; 2022; 21():15330338221117389. PubMed ID: 36529949
    [No Abstract]   [Full Text] [Related]  

  • 47. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
    He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
    Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
    J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with Hepatocellular carcinoma undergoing surgical treatment.
    Hsiao JH; Tsai CC; Liang TJ; Chiang CL; Liang HL; Chen IS; Chen YC; Chang PM; Chou NH; Wang BW
    Int J Surg; 2017 Sep; 45():35-41. PubMed ID: 28728985
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
    Miyaki D; Kawaoka T; Aikata H; Kan H; Fujino H; Fukuhara T; Kobayashi T; Naeshiro N; Honda Y; Tsuge M; Hiramatsu A; Imamura M; Hyogo H; Kawakami Y; Yoshimatsu R; Yamagami T; Awai K; Chayama K
    J Gastroenterol Hepatol; 2015 Apr; 30(4):726-32. PubMed ID: 25311578
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
    Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
    [No Abstract]   [Full Text] [Related]  

  • 52. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Ouyang G; Pan G; Xu H; Wu Y; Liu Z; Lu W; Yi B; Chen X
    J Clin Gastroenterol; 2020 Sep; 54(8):675-681. PubMed ID: 32569032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
    Shiozawa K; Watanabe M; Ikehara T; Kogame M; Matsui T; Okano N; Kikuchi Y; Nagai H; Ishii K; Makino H; Igarashi Y; Sumino Y
    Hepatogastroenterology; 2014 Jun; 61(132):885-91. PubMed ID: 26158136
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Kong SY; Song JJ; Jin YQ; Deng MJ; Yan JX
    Acta Clin Belg; 2023 Apr; 78(2):171-179. PubMed ID: 35587164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
    Saeki I; Yamasaki T; Tanabe N; Iwamoto T; Matsumoto T; Urata Y; Hidaka I; Ishikawa T; Takami T; Yamamoto N; Uchida K; Terai S; Sakaida I
    PLoS One; 2015; 10(5):e0126649. PubMed ID: 25992784
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
    Pan Y; Mei J; Chen J; Zhang D; Wang J; Wang X; Yi M; Zhou Z; Zhang Y; Chen M; Guo R; Xu L
    Ann Surg Oncol; 2022 Mar; 29(3):2016-2029. PubMed ID: 34637058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
    Park JY; Ahn SH; Yoon YJ; Kim JK; Lee HW; Lee DY; Chon CY; Moon YM; Han KH
    Cancer; 2007 Jul; 110(1):129-37. PubMed ID: 17508408
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma by placing a temporary catheter via the subclavian route.
    Liang HL; Huang JS; Lin YH; Lai KH; Yang CF; Pan HB
    Acta Radiol; 2007 Sep; 48(7):734-40. PubMed ID: 17729003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review.
    Zhang W; Ouyang D; Huang Z; Che X
    Front Oncol; 2023; 13():1085166. PubMed ID: 36776344
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Radiologic and Clinical Factors Predictive of Survival.
    Kim B; Won JH; Kim J; Kwon Y; Cho HJ; Huh J; Kim JK
    AJR Am J Roentgenol; 2021 Jun; 216(6):1566-1573. PubMed ID: 33852336
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.